Entries by Max

Soon to Be Phase 1 Trial: FX‑111, A Selective ARon Degrader with the Potential to Rethink Androgen Deprivation in Prostate Cancer

/in , , /by

A novel approach to targeting androgen receptor signaling in prostate cancer is emerging with FX‑111, an experimental degrader that selectively removes the hormone‑bound, transcriptionally active form of the receptor known as ARon. In metastatic castration‑resistant prostate cancer (mCRPC), the androgen receptor remains a central driver in the vast majority of cases, yet resistance to current […]

Darolutamide Linked to Better Real‑World Outcomes than Enzalutamide or Apalutamide in nmCRPC

/in , /by

A large real‑world study in nonmetastatic castration‑resistant prostate cancer (nmCRPC) called DEAR‑EXT, published on Nature, has added new detail to how the three androgen receptor inhibitors (darolutamide, enzalutamide, and apalutamide) behave outside of randomized trials, using data from over 1,300 men treated in US urology practices between 2019 and 2023. The analysis builds on an […]

AI CellVoyager Agent Turns Single‑Cell RNA‑seq Data into Continuous Hypothesis Generation

/in /by

CellVoyager shows that AI can move from “run what I tell you” to “decide what’s worth doing next” in data analysis for single‑cell RNA‑seq. It acts like a junior comp‑bio postdoc: it reads your background, sees which analyses you already did, plans additional steps, runs them, and proposes biological hypotheses such as new pathway associations […]

SonoPIN: Ultrasound‑Guided Microbubbles Deliver Large Cancer Drugs with Pinpoint Precision

/in , /by

Researchers at Duke University have developed a new ultrasound‑based method called SonoPIN (“Sonoporation‑assisted Precise Intracellular Nanodelivery”) that helps large anticancer molecules get inside tumor cells with high precision, while causing minimal damage to healthy tissue. In early lab experiments, the technique killed about half of the targeted cancer cells, while more than 99% of non‑targeted […]

Enolen Implant Cuts Localized Prostate Tumor Volume by 84% in Early Study

/in , , /by

Enolen is an investigational anti‑androgen implant designed to deliver enzalutamide directly inside the prostate, aiming to shrink localized prostate tumors while minimizing systemic exposure to the drug. In data from a National Cancer Institute–led phase‑1 study, the device produced an 84% reduction in measurable tumor volume on MRI over roughly five weeks in men scheduled […]

A New CAR‑T Strategy for Bone Cancer That May Help Metastatic Prostate Disease

/in , /by

Scientists have developed a promising new CAR‑T cell therapy for osteosarcoma, the most common bone cancer in children, adolescents, and young adults, and the work carries a cautiously optimistic signal for other solid tumors, including metastatic prostate cancer. In a preclinical study, researchers at Case Western Reserve University and University Hospitals engineered T cells to […]

Newsletter 11/2026

/in /by

LAST WEEK TODAY! A summary of what was published on ProstateWarriors.com during the past week Hi fellow warriors! Here we are again. We fall, we get back up, we gather our strength, and we move forward. Another week of encouraging news, my friends. Stay strong and fight on! As usual, we also have a podcast if you […]

Blood Lipid Profiles in Metastatic Prostate Cancer: A Window into Tumor Metabolism and Response to Enzalutamide

/in /by

A recent study, published on Nature, in metastatic castration‑resistant prostate cancer (mCRPC) shows that a simple blood test can reveal important information about how the tumor is reprogramming its metabolism and how it responds to enzalutamide, a common androgen‑receptor‑targeting drug. Researchers analyzed the entire circulating “lipidome” (the full panel of fats and related molecules in […]

Organoids from Routine TUR‑P Samples: A Personalized Platform for Prostate Cancer Therapy Testing

/in /by

A new preclinical study shows how a simple tissue sample can be turned into a powerful tool for understanding and treating advanced prostate cancer. Researchers have developed a method to grow patient‑derived organoids from prostate tissue fragments removed during routine transurethral resection of the prostate, or TUR‑P, a common procedure often done for urinary symptoms. […]